IRS2 and breast carcinoma: In contrast, IRS2 expression is elevated in more aggressive subtypes such as Basal/Triple Negative Breast Cancer (TNBC), and the membrane-localized expression of IRS2 is associated with reduced overall survival of breast cancer patients (8, 9).